Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Status:
Terminated
Trial end date:
2017-06-21
Target enrollment:
Participant gender:
Summary
The objectives of this study are twofold
- To evaluate the safety and efficacy of 0.1% AGN-195263 administered twice daily compared
to its vehicle in patients with evaporative dry eye (EDE)
- To evaluate the systemic pharmacokinetics of 0.1% AGN-195263 administered twice daily in
patients with EDE